At CCG, we believe that increasing amounts of clinical and genomic data have the potential to enable oncologists to make smarter decisions about which drug to use in which circumstance. To power our analytics, we carry out research at the cutting edge of machine learning and cancer genomics. Find out about our latest projects, how to collaborate with us, or request access to some of our open-source tools here.

Making liquid biopsy and artificial intelligence technologies work together could help doctors make faster decisions to treat cancer on time. Philip talked to the CEO of Cambridge Cancer Genomics to find out what this approach can mean for the treatment of cancer. Although much progress has been made in recent years, cancer remains one of the most dreaded diagnosis. For many types of cancer, current treatment options only alleviate symptoms or stop working after a while, only delaying the inevitable for a few months. One of the biggest challenges to treating cancer is its ability to rapidly mutate.